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Abstract
A recently synthesized vanadyl(IV) complex with aspirin [VO(aspirin)ClH2O]2, has been thoroughly investigated
by physicochemical techniques. In order to support the proposed structure, stoichiometry and the coordination
sphere of the vanadium center, some studies such as elemental analysis, electronic (diffuse reflectance) and
vibrational (infrared) spectroscopies, magnetic susceptibility, as well as the thermal behavior, were carried out.
The bioactivity of the vanadium complex (VOAspi) was evaluated on two osteoblast-like cell lines in culture,
being its cytotoxic effects stronger than the vanadyl cation as assessed by morphological changes and lipid per-
oxidation. These effects may be partially explained through the induction of the expression of Erks (Extracellular
signal-regulated kinases) and the inhibition of the PTPases (Phosphotyrosine phosphatases) present in the cellular
extracts.
Introduction
Vanadium is a trace transition metal with relavant
biological properties since it can interact with dif-
ferent biomolecules in its anionic and cationic forms
(Chasteen 1990). Our interest in the coordination
chemistry and biological effects of vanadium com-
pounds has been stimulated by the discovery of its
insulin mimetic properties and potential therapeutic
applications (Shechter 1990; Srivastava & Chiasson
1995). For instance, vanadium regulates the glu-
cose level in the blood of diabetic laboratory animals
and diabetic patients (Stern et al. 1993; Goldfine
et al. 1998). It modulates cellular metabolic processes
such as glucose uptake and glucose oxidation, lipid
metabolism, and also proliferative events like mito-
genesis and cellular differentiation. However, high
doses and chronic treatment with vanadium can cause
toxic effects (Domingo 2000). Even though the pre-
cise mechanism involved in the biological effects of
vanadium compounds is still uncertain, experimental
data support the hypothesis that these compounds ex-
ert their actions by regulating the cellular levels of
tyrosine phosphorylation. Vanadium derivatives may,
indirectly, enhance the levels of tyrosine phospho-
rylated proteins by inhibiting protein tyrosine phos-
phatases (PTPases) (Gresser & Tracey 1990; Krejsa
et al. 1997), subsequently inducing many biological
effects. On the other hand, when vanadium enters the
organism of vertebrates through the gastrointestinal
and respiratory tracts, is absorbed by and distrib-
uted throughout the tissues, being mainly accumulated
in bones, kidneys and liver (Etcheverry & Cortizo
1998; Nriagu 1998). Moreover, it has been previously
reported that vanadium deficiency causes impaired
growth and skeletal deformations (Nielsen 1995).
Aspirin, a compound that is largely produced
by the pharmaceutical industry, is used as an effec-
tive antipyretic, analgesic and antiinflammatory drug.
Copper complexes of antiinflammatory drugs have
been found to be more potent and desirable than
the parent ligands themselves (Brown et al. 1980;
Sorenson 1982). Preliminary results of the synthe-
sis and physicochemical characterization of a new
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vanadyl(IV)/aspirin complex (VOAspi) as well as its
biological effects on bone related cells, were previ-
ously and partially reported (Etcheverry et al. 2000).
In osteoblast-like cells, vanadium(IV) caused a slight
but statistically significant increase in cell prolifera-
tion, VOAspi being more potent than vanadyl cation.
However, at high concentrations both compounds in-
hibited MC3T3E1 non transformed cells, while only
VOAspi caused a cytotoxic effect on UMR106 os-
teosarcoma cells. The VOAspi complex induced a
dose-dependent decrease in the osteoblast differen-
tiation as assessed by alkaline phosphatase activity
(ALP).
The aims of this study were to analyze the mag-
netic and thermogravimetric properties of VOAspi as
well as to study in detail its infrared and diffuse
reflectance spectra. Also, the cytotoxic effects and
the possible mechanism involved in VOAspi bioac-




Vanadium(IV) oxide sulfate (vanadyl sulfate) was pro-
vided by Merck (Darmstadt, Germany), VOCl2 (Carlo
Erba) 50% aqueous solution was used without fur-
ther purification. Acetylsalicylic acid (Aspirin) was
provided by SIGMA Chemical Co. (St. Louis, Mis-
souri). Tissue culture material was from Corning
(Princeton, New Jersey), Dulbecco’s Modified Eagles
Medium (DMEM), trypsin-EDTA (ethylendiaminete-
tracetic acid) from Gibco (Gaithersburg, Maryland)
and fetal bovine serum (FBS) from Gen (Argentina).
All other chemicals used were of analytical grade from
Sigma.
Rabbit polyclonal anti-Erks (extracellular signal-
regulated kinases) antibody was from Santa Cruz
Biotechnology (Santa Cruz, California). Biotin con-
jugated antirabbit polyclonal antibody, avidin-alkaline
phosphatase and substrate solution: 5-Bromo-4-
chloro-3-indolyl phosphate (BCIP) plus nitroblue
tetrazolium (NBT) were from Vectastain (ABC kit,
Vector Laboratories Inc., Burlingame, California).
VOAspi was synthesized as previously reported
(Etcheverry et al. 2000).
Physicochemical characterization of VOAspi
Diffuse reflectance spectrum was measured on a Shi-
madzu UV-300 spectrophotometer, with MgO as stan-
dard.
Infrared (IR) spectra were recorded on a Perkin-
Elmer 580B spectrophotometer. The solid complex
was measured using the KBr technique.
Room temperature magnetic susceptibility was de-
termined with a Cahn-2000 balance, calibrated with
Hg[Co(SCN)4] and at a magnetic field strength of
6 kG.
Thermogravimetric (TG) and differential thermal
analysis (DTA) were performed on a Shimadzu ther-
moanalytical system (models TG 50 and DTA 50).
Alumina was used as a DTA standard. Measurements
were performed under an oxygen flow (60 ml min−1)
using Pt-crucibles at a heating rate of 10 ◦C min−1.
Cell culture
Osteoblastic non transformed mouse calvaria
(MC3T3E1) and rat osteosarcoma (UMR106) de-
rived cells were grown in DMEM supplemented with
100 U ml−1 penicillin, 100 µg ml−1 streptomycin and
10% (v/v) FBS at 37 ◦C, 5% CO2. When 70–80%
confluence was reached, cells were subcultured using
0.1% trypsin – 1 mM EDTA in Ca+2 – Mg+2 free
phosphate buffered saline (PBS) (Cortizo & Etchev-
erry 1995, Etcheverry et al. 1997). In our experiments,
cells were grown in six-well plates at a density of 2.5×
104 cells well−1. When cells reached 70% conflu-
ence, the monolayers were washed twice with DMEM.
Cells were incubated overnight with vanadium com-
pounds at different doses in serum free DMEM. In
order to test the biological effects, fresh stock solu-
tions of vanadyl(IV) sulfate or VOAspi were prepared
with distilled water at 10 or 100 mM concentration as
it was previously described (Etcheverry et al. 1997;
Etcheverry et al. 2000).
Whole-cell homogenate and cell fraction preparation
MC3T3E1 osteoblast-like cells were grown to con-
fluency in 150 cm2 flasks. Cells were washed with
PBS, resuspended in a homogenizing buffer (25 mM
Tris, 250 mM sucrose, 2 mM EDTA, 5 mM β-
mercaptoethanol, 1 mM phenyl-methyl-sulphonyl-
fluoride (PMSF), pH 7.4), and sonicated three times
for 60 s. The homogenate was centrifuged at 1, 000×g
for 10 min, and supernatant was further centrifuged
at 10, 000 × g at 4 ◦C for 30 min. Membranes were
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then isolated from the supernatant by centrifugation
at 105, 000 × g for 60 min at 4 ◦C. The resulting
pellet was solubilized in 0.1% Triton X-100/PBS. Pro-
tein concentration in both supernatant and membrane
fractions was determined by the Bradford’s (1976)
method. This material was stored at −20 ◦C until
PTPase activity was determined.
Cytotoxicity
Cells growing into six well plates were incubated
overnight with vanadium compounds in serum-free
DMEM or media alone (control or basal condition).
After two washes with PBS, monolayers were fixed
with methanol for 5 min at room temperature and
stained with 1:10 dilution of Giemsa for 10 min. Fi-
nally, plates were washed with water and morpholog-
ical changes induced by vanadium compounds were
observed by light microscopy (Sálice et al. 1999).
Lipid peroxidation. TBARS (Thiobarbituric acid
reactive species) production
To measure the extent of lipid peroxidation, TBARS
production was evaluated as it was previously de-
scribed (Cortizo et al. 2000a), by using Ohkawa’s
(1979) method. Cell extract protein content was as-
sessed by Bradford’s (1976) method. Lipid peroxide
levels were expressed in terms of nmol of malon-
dialdehyde produced per mg protein, using 1,1,3,3-
tetramethoxypropane as standard.
Detection of Erks by western blot
After incubation with or without vanadium deriv-
atives, cells were washed with cold PBS pH 7.4,
scraped in the sample buffer [0.0625 M tris(hydroxy-
methyl)-aminomethane (Tris) – HCl, pH 6.8, 2% SDS,
5% 2-mercaptoethanol, 0.001% bromophenol blue,
10% glycerol] and boiled for 5 min (Laemmli 1970).
Then, 50 µl of the extract (corresponding to 100 µg
protein) were subjected to electrophoresis on 12.5%
sodium dodecylsulfate (SDS) – polyacrylamide gels
(PAGE). A sample corresponding to basal condition
was included in each experiment. Then, proteins were
transferred onto nitrocellulose overnight at 70 mA.
Immunological determinations were performed us-
ing rabbit polyclonal anti-Erk as primary antibody.
In order to control loading and transfer, the mem-
branes were reversibly stained with 0.2% Ponceau S in
3% thrichloroacetic acid before the blocking (Cortizo
et al. 2000b). After 3 washes with water, filters were
blocked by incubation with 3% non-fat milk in PBS
(pH 7.4) for 30 min at room temperature. Antibody
binding was performed in TBS (Tris-buffered saline)
with 1% bovine serum albumin (BSA), overnight at
4 ◦C, using a 1:500 dilution. Filters were washed four
times with PBS for 15 min and incubated with biotini-
lated antirabbit second antibody (1:2,000) in TBS-1%
BSA for 30 min at room temperature. After washing
them four times with PBS, nitrocellulose was incu-
bated with avidin-alkaline phosphatase for 30 min at
room temperature and then washed four times with
PBS. Visualization was performed by incubating the
filters with alkaline phosphatase substrates NBT-BCIP
until the color developed.
PTPases activity measurement
This activity was estimated by the potency of cell ex-
tract (50 µg protein ml−1) to hydrolyze p-nitrophenyl
phosphate (pNPP) according to Li et al. (1996). The
assay (final volume 1 ml) consisted of 5 mM pNPP
in 50 mM HEPES (N-(2-hydroxyethyl)-piperazine-
N0-(2-ethanesulfonic acid)), pH 7.5, enzyme source
and different concentrations (0–100 µM) of vanadium
compounds. After 30 min of incubation period, optical
density was measured at 405 nm. In addition, the ef-
fects of vanadium compounds on the alkaline PTPase
present in the cell extract were also assayed by using a
glycine buffer pH 10.5.
Statistical analysis
At least three independent experiments were per-
formed by triplicate for each experimental condition.
Data were expressed as mean ± SEM (n = 9).
Statistical differences were analyzed using Student’s
t-test.
Results and discussion
Physicochemical properties of VOAspi
In order to obtain a deeper insight into the physic-
ochemical properties of the VOAspi complex, the
following determinations were performed:
Elemental analysis
Calc. for C18H18Cl2O12V2 (599): C, 36.00; H, 3.00;
V, 17.03; Cl, 11.85. Found: C, 36.26; H, 3.16; V,
16.95; Cl, 12.05%.
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Table 1. Characteristic IR vibrations for Aspirin and VOAspi.
Aspirin VOAspi Assignments
(cm−1) (cm−1)
2984 m 2980 m νasCH3
2940 m 2933 m νasCH3
2910 m 2908 m νsCH3
1754 s 1768 sh νC = O (−C(O)OCH3), Fermi
1745 s resonance (see text)
1690 vs νC = O (−COOH)
1592 s δOH2
1537 s νasCOO−
1482 w 1482 w δipPhH, νCC, τH3CCO, δasCH3
1458 s 1450 m τH3CCO,δasCH3
1419 m See text δsCH3
1403 vs νsCOO−
1305 vs 1297 vw νC-O (−COOH)
988 s νV = O
vs = very strong, s = strong, m = medium, w = weak, vw =
very weak, sh = shoulder.
Diffuse reflectance
The spectrum of the solid complex presents two
broad and not well-defined bands at 810 and 610 nm.
This pattern agrees with that of VOAspi in solution
(Etcheverry et al. 2000). The shift of the two typi-
cal bands of the free vanadyl(IV) cation (Ballhausen
& Gray 1962; Lever 1984) to red and blue, respec-
tively, suggests coordination of this metal through the
carboxylate groups of the ligand (Johnson & Shep-
herd 1978; Ferrer et al. 1993; Kögerler et al. 1996;
Williams et al. 1998; Allegretti et al. 2000). As the
position of the electronic absorption bands either in
solution or in solid state are found to be quite similar, it
can be assumed that the structure of the solid complex
is retained upon dissolution.
Infrared (IR) spectroscopy
Table 1 shows the characteristic vibrations for Aspirin
and VOAspi complex. The IR spectrum of Aspirin
has been assigned according to previous reported data
(Binev et al. 1990). The bands at 2984 and 2940 cm−1,
corresponding to the antisymmetric stretching of the
methyl group, remain unchanged in the VOAspi com-
plex. A similar result was observed with the νs vi-
bration of this group. The C=O stretching band at
1754 cm−1 presents a clearly defined shoulder in the
complex, probably due to Fermi resonance. These fea-
tures indicate that the acetyl group remains intact upon
complex formation. This behavior is different from
that observed in the case of uranyl (UO2+2 ), Bi3+ and
Zn2+ complexes of the acetylsalicylic acid in which
the coordination takes place through the carboxylic
and the acetyl groups (Baslas et al. 1979). On the
other hand, the carboxylic group stretching band of
the ligand is replaced by two vibrations corresponding
to the antisymmetric and symmetric stretchings of the
carboxylate group in the complex. The free aspirinate
anion presents a 1[νas(CO
−
2 )−νs(CO−2 )] = 239 cm−1.
The 1 value for VOAspi is 134 cm−1, indicating
that the carboxylate groups behave as bidentate lig-
ands, suggesting the formation of a binuclear species
(Carvill et al. 1989; Lin-Vien et al. 1991; Nakamoto
1997).
The band of the complex located at 1592 cm−1 has
been assigned to the bending vibration of the water
molecule since it disappears by heating at 140 ◦C.
Moreover, in the complex, the strong and broad sym-
metric stretching band of the carboxylate group masks
the symmetric bending of the methyl group placed at
1419 cm−1 in the Aspirin spectrum.
On the other hand, another remarkable change oc-
curs with the C-O stretching band of the carboxylic
acid (1305 cm−1, vs) (Lin-Vien et al. 1991). It can be
observed a slight frequency shift and a strong inten-
sity decrease through coordination to the vanadyl(IV)
cation. Moreover, the V = O stretching is observed as
a new and strong band at 988 cm−1.
Magnetic susceptibility (room temperature): 1.34 BM
per vanadium atom
This subnormal magnetic moment value may be due
to an antiferromagnetic exchange between the d1 elec-
tron of each metallic center of the dimer. In addition,
the presence of bridging carboxylate groups may force
vanadium ions to come close together. Exchange inter-
actions may then occur by 5 overlap of the vanadium
dxy orbital with the 5 symmetry orbitals of the COO−
groups (Syamal 1975).
Thermal behavior
A typical thermogram under an oxygen flow is shown
in Figure 1. As can be seen, two successive degrada-
tion steps are observed (67 ◦C and 167 ◦C). At 210 ◦C
the complex has given up nearly 18.4% of its mass,
which corresponds to the loss of ca. 2 moles of water
and 2 moles of HCl (calculated = 18.2%). The last two
steps, which are extended up to 400 ◦C, are related to
the exo DTA-peaks located at 260 and 355 ◦C.
Total thermal degradation can be represented by the
following equation:
[VO(aspirin)CIH2]2
O2,φ−→ V2O5 + volatile products
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Fig. 1. TG and DTA curves for the solid [VO(aspirin)ClH2O]2 complex. O2 flow: 60 ml/min; heating rate: 10
◦C min−1
Fig. 2. Proposed structure for VOAspi complex.
The residual mass found was 30.8%, which is in
agreement with the theoretical value of 30.4%. The
generation of V2O5 as the only solid residue was con-
firmed by IR spectroscopy. On the other hand, the
weak endothermic peak observed in the thermogram at
ca. 650 ◦C quite agrees with the fusion temperature of
V2O5 (658 ◦C) (Clark 1973). The proposed stoichiom-
etry and composition of the VOAspi complex has also
been confirmed by the results of the thermal analysis.
The structure shown in Figure 2 can be suggested
on the basis of the physicochemical studies. It can be
seen that each vanadium(IV) atom of the dimer shows
a square pyramid as its coordination sphere. Each
vanadium(IV) coordinates with the oxygen atom of
the vanadyl group, two oxygens from the carboxylate
bridging groups, one oxygen from the water molecule
and one chloride anion.
Cytotoxic effects
As we have previously reported (Barrio et al. 1997;
Etcheverry et al. 1997; Sálice et al. 1999), vana-
dium compounds induced morphological changes in
MC3T3E1 cells. These cells show (Figure 3A) a fi-
broblastic shape with multiple processes connecting
each other and also well defined nuclei with nucle-
oli. The effects of 10 µM VO in MC3T3E1 cells
after 24 h incubation such as changes in the normal
phenotype, as the loss of some intercellular connec-
tions and condensation of cytoplasms, can be seen in
Figure 3B. More pronounced alterations with similar
characteristics were induced by VOAspi (Figure 3C).
These observations parallel the effect of these vana-
dium compounds on cell proliferation (Etcheverry
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et al. 2000) and suggest a stronger cytotoxic effect of
VOAspi in comparison with the vanadyl(IV) cation.
Mechanism of action of VOAspi: Lipid peroxidation
The role of the oxidative mechanisms in the vanadium-
induced cytotoxicity was evaluated in the osteoblast-
like cells by assessing TBARS formation. Figure 4A
and B show that VO and VOAspi increased lipid per-
oxidation in a concentration-dependent manner. In
both cell lines, UMR106 and MC3T3E1, VOAspi was
more potent than VO at doses lower than 2.5 mM.
We have previously shown (Cortizo et al. 2000a)
that vanadate-induced cytotoxicity is partially depen-
dent on oxidative stress. A negative correlation was
found between cell survival and TBARS formation.
In this study, we have also observed that there is an
association between TBARS level induced by VOAspi
and its cytotoxic effects, suggesting a role for the lipid
peroxidation in the VOAspi mechanism of action.
Effect of vanadium on Erk-1 and Erk-2 expression
Vanadium compounds inhibit PTPases and conse-
quently prevent dephosphorylation and cause a rapid
increase in the phosphorylation of tyrosine residues of
multiple proteins. Like insulin, vanadium induces the
phosphorylation and activation of docking molecules
like IRS-1 and Src, leading in turn to activation of
the signaling cascade of the mitogen activated protein
kinases (MAPK) (White & Kahn 1994; Pandey et al.
1999).
In osteoblast-like cells, vanadium compounds pro-
mote the tyrosine phosphorylation of several proteins
(Sálice et al. 1999). To examine whether the expres-
sion of Erks is regulated by vanadium, Erk-1 and −2
were analyzed by Western blot. UMR106 osteoblast-
like cells were treated with VO and VOAspi durig dif-
ferent incubation periods (Figure 5). Both compounds
induced the expression of Erk-1 and -2, detected as
44- and 42-kDa proteins, in a time-dependent manner
(Figure 5A and B). The quantification of these bands
showed the highest stimulation between 10 and 30 min
for VO and VOAspi (Figure 5C and D). The treatment
with VO and VOAspi for 10 min increased the ex-
pression of Erk-1 and -2 in a dose-response manner
(Figure 6A and B). The expression of Erks was depen-
dent on the concentration of vanadium, attaining its
maximum between 250–500 µM for both compounds
(Figure 6C and D).
In the non-transformed MC3T3E1 cells, VO and
VOAspi caused a time- and dose-response induction
Fig. 3. Effect of vanadium compounds on MC3T3E1 cell mor-
phology. Osteoblasts were incubated in serum free DMEM without
addition (A), with 10 µM vanadyl (B) or with 10 µM VOAspi (C).
Cells were stained with Giemsa. Obj. 40X.
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Fig. 4. Vanadium induced-lipid peroxidation in UMR106 (A) and MC3T3E1 (B) osteoblast-like cells. Cells were incubated in a serum-free
DMEM with or without different vanadium concentrations at 37 ◦C for 4 h. TBARS was assessed as described in Material and Methods.
Results are expressed as% basal and represent the mean ± SEM (n = 6).
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Fig. 5. Kinetics of vanadium effects on Erks expression. UMR106 cells were serum starved for 24 h and then incubated in DMEM with 1 mM
VOAspi (A) or 1 mM vanadyl (B) for 0 to 120 min. Cell extracts were separated by 12.5% SDS-PAGE and analyzed by Western blot. Erk-1
(44 kDa band) and Erk-2 (42 kDa band) are indicated in the figures. Images were scanned and analyzed by the Scion-beta 2 program (C and
D). The relative intensity of each band is presented as % basal as a function of the incubation time.
of Erks. Maximal stimulation of ERK-1 and −2 was
observed between 10 and 20 min (data not shown).
VOAspi caused a lower expression of Erks than VO in
the range of 0–200 µM. However, the opposite effect
was observed at doses >250 µM.
All these results demonstrated that VOAspi can in-
duce the Erk signaling pathway in osteoblast-like cells
and suggest that this mechanism may be involved in
its bioactivity.
Effect on PTPase activity of osteoblast fraction
Increasing evidence points towards a major role of
PTPases in the mechanisms of action of different vana-
dium compounds (Gresser & Tracey 1990; Huyer
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Fig. 6. Dose-response curves of the effect of vanadium compounds on Erks expression. UMR106 cells were serum starved for 24 h and then
incubated in DMEM with different doses of VOAspi (A) or vanadyl (B) at 37 ◦C for 10 min. Western blot of Erk-1 (44 kDa) and Erk-2
(42 kDa) are shown. The relative intensity was analyzed and ploted for VOAspi (C) and vanadyl (D) as% basal, as a fuction of the vanadium
concentration.
et al. 1997). In order to further investigate signal-
ing pathways involved in the new vanadium complex
(VOAspi) bioactivity, we studied the effect of VO and
VOAspi on the kinetics of inhibition of alkaline and
neutral PTPases from cytosol and particulate fractions
of osteoblast-like cells.
Figures 7 and 8 show that both compounds inhib-
ited alkaline and neutral PTPases in a dose-response
manner. In the cytosolic fraction, the former enzyme
was equally inhibited by both vanadium compounds
(Figure 7A). At concentrations <20 µM and >80 µM,
VOAspi was a stronger inhibitor than VO. Contrary,
upon microsomal alkaline PTPase activity, VO caused
a stronger effect than VOAspi (Figure 7B).
On the other hand, vanadium compounds were
weak inhibitors of neutral PTPases (Figure 8A and B).
VO and VOAspi had the same inhibition potency for
cytosolic neutral PTPase (Figure 8A), although at low
concentrations (5–10 µM), VO proved to be stronger
than VOAspi. On the other hand, in the microsomal
fraction, VOAspi had a more potent inhibitory effect
on the neutral PTPases , reaching a 25–30% inhibition
within the 25–100 µM concentration range. A slight
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Fig. 7. Effect of vanadium compounds on alkaline PTPase activity in cellular fractions of MC3T3E1 cells. Cytosolic (A) and microsomal (B)
fractions were incubated with pNPP in buffer pH 10.5 with different vanadium concentrations, to evaluate alkaline PTPases. Data represent
mean ± SEM, (n = 8).
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Fig. 8. Effect of vanadium compounds on neutral PTPase activity in cellular fractions of MC3T3E1 cells. To evaluate neutral PTPase, cytosolic
(A) and microsomal (B) fractions were incubated with pNPP in buffer HEPES pH 7.5 with different vanadium concentrations. Data represent
mean ± SEM, (n = 8).
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effect was observed for VO, which attained the 25% of
inhibition at a concentration of 100 µM (Figure 8B).
These results demonstrated that PTPases present in
osteoblast extracts can be inhibited by VOAspi com-
plex and this may be the mechanism that can activate
the tyrosine phosphorylation pathway in osteoblast-
like cells.
Vanadium compounds have been widely used as
general PTPase inhibitors, although their mechanism
of action has not been investigated in detail. For in-
stance, vanadate is a phosphate analog and adopts a
trigonal bipyramid structure, similar to that of the tran-
sition state of the enzymes participating in the phos-
phate metabolism (Gresser & Tracey 1990). On the
other hand, pervanadates are stronger insulin-mimetic
agents and contain one or more chelating ligands in
addition to the oxo and peroxo ligands (Posner et al.
1994). Recently Huyer et al. (1997) have shown that
vanadate and pervanadate inhibit PTPases through
completely different mechanisms. While vanadate was
demonstrated to be a competitive and reversible in-
hibitor for purified PTP1B, pervanadate irreversibly
inhibited this activity by oxidizing a key cysteine.
On the other hand, bis(maltolato)-oxovanadium(IV)
(BMOV), in which the vanadium atom has a square
pyramidal coordination sphere is also a strong PTPase
inhibitor (Krejsa et al. 1997).
Even though the inhibition of purified PTPases
by vanadium(IV) has not been completely investi-
gated, the vanadium(IV) is probably much less potent
than vanadium(V). In our study, the PTPase activ-
ity assayed at neutral pH in the microsomal fraction
seems to be more sensitive to VOAspi than VO (Fig-
ure 8B). VOAspi may have a strong affinity for the
neutral PTPase present in this fraction. Another possi-
ble mechanism involved in the cytotoxic effects could
be the generation of oxidative stress. Thus, VOAspi
could be a more potent oxidizing agent than VO,
entering in a redox-cycling and generating reactive
oxygen/nitrogen species. This seems to be the case,
since VOAspi was a stronger inductor of lipid per-
oxidation in both osteoblast cell lines. The evidence
suggests that the oxidative stress could be involved in
the cytotoxic effect of VOAspi complex when used at
high concentrations.
Conclusions
It is well known that vanadium compounds have
insulin- and growth factor-mimetic actions in living
organisms and different types of cells in culture. How-
ever, they also show toxic effects at high doses or
in prolonged administration. Moreover, vanadyl(IV)
cation has less toxic effect than vanadium(V), but it
is unstable under physiological pH. At present, scien-
tists are highly interested in developing new vanadium
derivatives with insulin-mimetic properties and less
adverse effects. Special attention is paid to the com-
plexation of vanadyl(IV) cation with organic ligands
in order to improve its biodisponibility and beneficial
effects.
In the complex [VO(aspirin)ClH2O]2, the coordi-
nation between aspirin and vanadyl(IV) cation takes
place through the deprotonated carboxylate groups
behaving as bidentated bridging ligands. The acetyl
group remains unchanged being this behaviour dif-
ferent from that of other metallic aspirinates. In the
suggested structure of the complex, the vanadium
atom presents a square pyramidal coordination sphere
like in other vanadium compounds (such as BMOV)
with similar mimetic properties.
In the osteoblast-like cells, VOAspi exerted more
potent cytotoxic effects than VO as assessed by mor-
phological changes, cell survival and lipid peroxida-
tion. These effects may be partially explained through
the expression of Erks and the inhibition of the PT-
Pases present in the cellular extracts.
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